Brief: Beroni Group Signs Agreement With Genscript Biotech To Conduct Study To Develop Nanobody-Based Medical Solution For COVID-19
12/08/2020 15:12
Aug 12 (Reuters) - Beroni Group Ltd BTG.NH :
* BERONI GROUP SIGNS AGREEMENT WITH GENSCRIPT BIOTECH
CORPORATION
TO CONDUCT FURTHER STUDY TO DEVELOP NANOBODY-BASED MEDICAL
SOLUTION FOR COVID-19
Source text for Eikon: ID:nGNX4yV5L0
Further company coverage: BTG.NH
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beroni
See all newsBrief: Beroni Group’s Enhanced Covid-19 Antigen Rapid Test Kit Received CE Certification
Brief: Beroni Group Ltd Files For A U.S. IPO
Received Part Payment Of A $1.07 Mln Order For SARS-COV-2 Antigen Test Kit From A Japanese Pharma Co
Brief: Beroni Group Gets Approval For R&D Rebate From Australian Government
Brief: Beroni Group Says Study Of Its SARS-CoV-2 Antigen Test Kit Showed Overall Sensitivity Of 95%